JP2024535692A5 - - Google Patents

Info

Publication number
JP2024535692A5
JP2024535692A5 JP2024509399A JP2024509399A JP2024535692A5 JP 2024535692 A5 JP2024535692 A5 JP 2024535692A5 JP 2024509399 A JP2024509399 A JP 2024509399A JP 2024509399 A JP2024509399 A JP 2024509399A JP 2024535692 A5 JP2024535692 A5 JP 2024535692A5
Authority
JP
Japan
Prior art keywords
antibody
hla
seq
heavy chain
light chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024509399A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024535692A (ja
Filing date
Publication date
Priority claimed from GBGB2111905.2A external-priority patent/GB202111905D0/en
Application filed filed Critical
Publication of JP2024535692A publication Critical patent/JP2024535692A/ja
Publication of JP2024535692A5 publication Critical patent/JP2024535692A5/ja
Pending legal-status Critical Current

Links

JP2024509399A 2021-08-19 2022-08-19 抗hla-g抗体 Pending JP2024535692A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2111905.2A GB202111905D0 (en) 2021-08-19 2021-08-19 Antibodies
GB2111905.2 2021-08-19
PCT/EP2022/073195 WO2023021187A1 (en) 2021-08-19 2022-08-19 Anti-hla-g antibodies

Publications (2)

Publication Number Publication Date
JP2024535692A JP2024535692A (ja) 2024-10-02
JP2024535692A5 true JP2024535692A5 (enExample) 2025-06-25

Family

ID=77913991

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024509399A Pending JP2024535692A (ja) 2021-08-19 2022-08-19 抗hla-g抗体

Country Status (16)

Country Link
US (1) US20250026836A1 (enExample)
EP (1) EP4388007A1 (enExample)
JP (1) JP2024535692A (enExample)
KR (1) KR20240046577A (enExample)
CN (1) CN118369341A (enExample)
AR (1) AR126820A1 (enExample)
AU (1) AU2022330347A1 (enExample)
BR (1) BR112024001989A2 (enExample)
CA (1) CA3227160A1 (enExample)
CL (1) CL2024000115A1 (enExample)
CO (1) CO2024001711A2 (enExample)
GB (1) GB202111905D0 (enExample)
IL (1) IL310245A (enExample)
MX (1) MX2024002069A (enExample)
TW (1) TW202315889A (enExample)
WO (1) WO2023021187A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025054312A1 (en) * 2023-09-05 2025-03-13 Tizona Therapeutics Hla-g antibodies in antibody-drug conjugates
EP4793288A1 (en) * 2023-10-12 2026-08-19 Imbiologics Corp. Antibody specifically binding to hla-g, and use thereof
GB202319122D0 (en) * 2023-12-14 2024-01-31 Kbio Holdings Ltd Antibody
CN121027507A (zh) * 2025-10-31 2025-11-28 杭州华得森生物技术有限公司 基于多抗体稳定预混液的多重免疫荧光染色试剂盒及其制备方法与应用

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
DK336987D0 (da) 1987-07-01 1987-07-01 Novo Industri As Immobiliseringsmetode
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
GB8719042D0 (en) 1987-08-12 1987-09-16 Parker D Conjugate compounds
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8907617D0 (en) 1989-04-05 1989-05-17 Celltech Ltd Drug delivery system
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
CA2090126C (en) 1990-08-02 2002-10-22 John W. Schrader Methods for the production of proteins with a desired function
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
EP0604580A1 (en) 1991-09-19 1994-07-06 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES
GB9120467D0 (en) 1991-09-26 1991-11-06 Celltech Ltd Anti-hmfg antibodies and process for their production
FR2716640B1 (fr) 1994-02-28 1996-05-03 Procedes Machines Speciales Dispositif de centrage et de blocage d'une pièce en vue de son rodage à l'aide d'un rodoir à expansion.
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
EP0979281B1 (en) 1997-05-02 2005-07-20 Genentech, Inc. A method for making multispecific antibodies having heteromultimeric and common components
EP1049787B1 (en) 1998-01-23 2004-11-24 Vlaams Interuniversitair Instituut voor Biotechnologie Multipurpose antibody derivatives
GB9812545D0 (en) 1998-06-10 1998-08-05 Celltech Therapeutics Ltd Biological products
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
JP2003516755A (ja) 1999-12-15 2003-05-20 ジェネンテック・インコーポレーテッド ショットガン走査、すなわち機能性タンパク質エピトープをマッピングするための組み合わせ方法
US6908963B2 (en) 2001-10-09 2005-06-21 Nektar Therapeutics Al, Corporation Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
EP1513879B1 (en) 2002-06-03 2018-08-22 Genentech, Inc. Synthetic antibody phage libraries
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
WO2004051268A1 (en) 2002-12-03 2004-06-17 Celltech R & D Limited Assay for identifying antibody producing cells
HUE035898T2 (en) 2002-12-16 2018-05-28 Genentech Inc Immunoglobulin variants and their applications
AU2004205631A1 (en) 2003-01-16 2004-08-05 Genentech, Inc. Synthetic antibody phage libraries
GB0303337D0 (en) 2003-02-13 2003-03-19 Celltech R&D Ltd Biological products
GB0312481D0 (en) 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
PT1644412E (pt) 2003-07-01 2015-12-23 Ucb Biopharma Sprl Fragmentos de anticorpos fab modificados
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
WO2005100402A1 (en) 2004-04-13 2005-10-27 F.Hoffmann-La Roche Ag Anti-p-selectin antibodies
GB0412181D0 (en) 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
GB0513852D0 (en) 2005-07-06 2005-08-10 Celltech R&D Ltd Biological products
EP1957531B1 (en) 2005-11-07 2016-04-13 Genentech, Inc. Binding polypeptides with diversified and consensus vh/vl hypervariable sequences
WO2007064919A2 (en) 2005-12-02 2007-06-07 Genentech, Inc. Binding polypeptides with restricted diversity sequences
EA015992B1 (ru) 2006-03-17 2012-01-30 Байоджен Айдек Эмэй Инк. Стабилизированное антитело и многовалентная антигенсвязывающая молекула на его основе, способы получения и использования вышеназванного стабилизированного антитела
EP2016101A2 (en) 2006-05-09 2009-01-21 Genentech, Inc. Binding polypeptides with optimized scaffolds
CN100592373C (zh) 2007-05-25 2010-02-24 群康科技(深圳)有限公司 液晶显示面板驱动装置及其驱动方法
EP2535350B1 (en) 2007-09-26 2018-01-24 UCB Biopharma SPRL Dual specificity antibody fusions
US10407513B2 (en) 2008-09-26 2019-09-10 Ucb Biopharma Sprl Biological products
WO2011030107A1 (en) 2009-09-10 2011-03-17 Ucb Pharma S.A. Multivalent antibodies
GB0920127D0 (en) 2009-11-17 2009-12-30 Ucb Pharma Sa Antibodies
GB0920324D0 (en) 2009-11-19 2010-01-06 Ucb Pharma Sa Antibodies
GB201000467D0 (en) 2010-01-12 2010-02-24 Ucb Pharma Sa Antibodies
GB201005064D0 (en) 2010-03-25 2010-05-12 Ucb Pharma Sa Biological products
PT2560993T (pt) 2010-04-20 2024-09-16 Genmab As Proteínas contendo anticorpo heterodimérico fc e métodos para a produção das mesmas
CN103429620B (zh) 2010-11-05 2018-03-06 酵活有限公司 在Fc结构域中具有突变的稳定异源二聚的抗体设计
JP6411214B2 (ja) 2011-11-11 2018-10-24 ユーシービー バイオファルマ エスピーアールエル アルブミン結合抗体及びその結合断片
EP2730588A1 (en) * 2012-11-12 2014-05-14 Intelectys Antibodies and fragments thereof raised against the alpha-3 domain of HLA-G protein, methods and means for their preparation, and uses thereof
GB201223276D0 (en) 2012-12-21 2013-02-06 Ucb Pharma Sa Antibodies and methods of producing same
GB201411320D0 (en) 2014-06-25 2014-08-06 Ucb Biopharma Sprl Antibody construct
GB201411420D0 (en) 2014-06-26 2014-08-13 Ucb Biopharma Sprl Antibody constructs
CA3025681A1 (en) * 2016-06-03 2017-12-07 Invectys Anti hla-g specific antibodies
TW201829463A (zh) * 2016-11-18 2018-08-16 瑞士商赫孚孟拉羅股份公司 抗hla-g抗體及其用途
EP3434688A1 (en) * 2017-07-24 2019-01-30 Commissariat à l'Energie Atomique et aux Energies Alternatives Hla-g transcripts and isoforms and their uses
AR114789A1 (es) 2018-04-18 2020-10-14 Hoffmann La Roche Anticuerpos anti-hla-g y uso de los mismos
BR112021005868A2 (pt) * 2018-09-27 2021-10-19 Tizona Therapeutics Anticorpos anti-hla-g, composições compreendendo anticorpos anti-hla-g e métodos de uso de anticorpos anti-hla-g

Similar Documents

Publication Publication Date Title
JP6526189B2 (ja) 抗pd−l1抗体並びにその治療及び診断のための使用
JP2025039661A (ja) 抗SIRPα抗体
CN105968206B (zh) 抗erbb3抗体
RU2013125459A (ru) АНТИТЕЛА ПРОТИВ БЕЛКА РЕЦЕПТОРА c-Met
JP2020511947A5 (enExample)
CA3020864A1 (en) Novel b7-h3-binding molecules, antibody drug conjugates thereof and methods of use thereof
JP2020530297A5 (enExample)
JP2018510636A5 (enExample)
US12227583B2 (en) Anti-OX40 antibody, antigen-binding fragment thereof, and the pharmaceutical use
US20260103536A1 (en) Anti-cd19/anti-cd38 common light chain bispecific antibodies
JP2013545455A5 (enExample)
JP2013502913A5 (enExample)
JP2021525544A5 (enExample)
JP7682247B2 (ja) 抗bcma抗体及びその用途
JP2022524588A5 (enExample)
RU2015115956A (ru) Антитела, специфичные в отношении фактора роста тромбоцитов в, и их композиции и применения
JPWO2018117237A1 (ja) 抗cd3抗体及び該抗体を含む分子
JP2024541680A5 (enExample)
JP2013509158A5 (enExample)
JP2022513043A5 (enExample)
JP2022528721A5 (enExample)
JP2013519690A5 (enExample)
CN111886023A (zh) 针对tim-3的抗体及其用途
JP2024533234A5 (enExample)
CN113637075B (zh) 双特异性抗原结合分子及其医药用途